Key result
Isoproterenol drives sustained cardiac fibrosis, hypertrophy, and cellular senescence in rats.
Why the study?
Surgical cardiac injury models induce cellular senescence in rodents but are complex and carry high mortality, necessitating simpler alternatives.
Does subcutaneous isoproterenol (100 mg/kg for 5 days) induce persistent cardiac injury, remodeling, and cellular senescence in young adult male Sprague-Dawley rats at 10 and 28 days?
Does subcutaneous isoproterenol (100 mg/kg for 5 days) induce persistent cardiac injury, remodeling, and cellular senescence in young adult male Sprague-Dawley rats at 10 and 28 days?
Subcutaneous administration of isoproterenol for five days in male Sprague-Dawley rats induces persistent cardiac fibrosis, hypertrophy, and cellular senescence lasting up to 28 days without mortality, providing a simple and cost-effective preclinical model for testing senolytic therapies.
Isoproterenol rat model induces persistent cardiac senescence; hypothesis-generating for human heart failure mechanisms and therapies.
Background/Objectives: Cardiovascular disease increases with ageing and remains the leading cause of death worldwide. Cellular senescence contributes to cardiac dysfunction in the older population by secreting the senescence-associated secretory phenotype (SASP). Cardiac injury models induced by surgery have been shown to induce senescence in young adult rodents. However, surgical models are complex and associated with high mortality. Methods: We established a rat model of injury and senescence using isoproterenol (ISO). Male SD rats received ISO (100 mg/kg) for five days, then hearts were collected on days 10 and 28 after the first ISO dose. Results: ISO administration caused cardiac injury, manifested by inflammatory infiltration, fibrosis, and increased cardiomyocyte cross-sectional area. Cardiac injury was accompanied by an increase in the senescence markers SA-β-gal, p16 and p21, and DNA damage marker γH2AX. Moreover, the mRNA levels of p21 increased on day 10, along with several SASP factors, whereas the mRNA levels of p16 increased on day 28. Fibrosis, hypertrophy, and senescence persisted until day 28, indicating long-lasting cardiac remodeling and senescent cell accumulation. Conclusions: These findings suggest that ISO can provide a simple, cost-effective platform for studying senescence and cardiac injury. This model facilitates the study of timing, dosage, mechanisms and efficacy of senolytic interventions and may contribute to the development of senescence-targeted therapies.
No takes yet. Share an insight, caveat, or question.
Altuwaijri et al. (2026) studied Cardiac injury and cellular senescence (n=40). Isoproterenol (ISO) vs. Saline was evaluated on Cardiac injury (cellular infiltration, collagen deposition, cardiomyocyte hypertrophy) and cellular senescence markers (SA-β-gal, p16, p21, γH2AX) (p=<0.05). Isoproterenol (100 mg/kg for 5 days) significantly increased cardiac fibrosis, hypertrophy, DNA damage (γH2AX), and senescence markers (SA-β-gal, p16, p21) through day 28 in rats (p < 0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: